The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

@article{Ono2001ThePL,
  title={The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.},
  author={Seiji Ono and Norio Kato and Yasushi Shiratori and Jun-ichi Kato and T Goto and Raymond F Schinazi and Flair Jos{\'e} Carrilho and Masao Omata},
  journal={The Journal of clinical investigation},
  year={2001},
  volume={107 4},
  pages={449-55}
}
After receiving lamivudine for 3 years to treat chronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant. The aim of this study was to evaluate the influence of these mutations on viral replication and resistance to antiviral agents. We investigated the replication fitness and susceptibility of the wild-type and five mutant HBVs (L528M, M552I, M552V, L528M/M552I, and L528M/M552V… CONTINUE READING